• SHARE

Last month, the owner of a small pharmacy in Greenbelt, Maryland, secured two dozen courses of Pfizer’s new medication for treating COVID-19, eager to quickly provide them to his high-risk customers who test positive for the virus.

More than a month later, the pharmacy, Demmy’s, has dispensed the anti-viral pills to just seven people. The remaining stock is sitting in neatly packed rows on its shelves in the suburbs of Washington. And the owner, Adeolu Odewale, is scrambling to figure out how to get the medication, Paxlovid, to more people, as cases have increased over 80% in Maryland in recent days.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)